News
-
30.08.2021Collaboration with LifeSci AdvisorsmoreCaptor Therapeutics S.A. has entered into an agreement with LifeSci Advisors LLC
-
29.06.2021Appointment of Radosław Krawczyk as Chief Financial OfficermoreThe Supervisory Board has appointed Radosław Krawczyk to the Company's Management Board and entrusted him with the function of CFO
-
22.06.2021Resignation of the CFO and the succession planmoreAleksandra Skibińska resigned from the position of the Member of the Management Board and Chief Financial Officer
-
16.04.2021WSE listing ceremony invitationmoreon the Warsaw Stock Exchange
-
09.04.2021Successful initial public offering of Captor Therapeutics S.A.morethe largest ever biotechnology company public offering on the Warsaw Stock Exchange
-
23.03.2021Captor Therapeutics S.A. rozpoczyna ofertę publiczną akcji (IPO)moreSpółka opublikowała 22 marca 2021 r. prospekt sporządzony w związku z ofertą publiczną
-
15.03.2021Captor Therapeutics S.A. is set to conduct a public offeringmoreand list its shares on the Warsaw Stock Exchange
-
01.03.2021Paweł Dobrzański, PhD, joins Captor Therapeutics S.A. as Biology Department DirectormorePawel Dobrzański, an international expert in molecular biology and drug development, will support our team!
-
20.01.2021Tom Shepherd as Chief Executive OfficermoreCaptor Therapeutics S.A. announces the appointment of Tom Shepherd, Ph.D., as Chief Executive Officer
-
22.12.2020Captor Therapeutics and Sosei Heptares Enter Strategic CollaborationmoreFocused on Targeted GPCR Degradation as Novel Approach for Drug Design